glp 1 semaglutide or tirzepatide Compounded Program: Results, Timeline & Comparison Semaglutide & tirzepatide are transforming

Mild nausea

The platform works with licensed medical providers who review each patient's health information carefully before approving treatment

Most areas need a series Read more Schedule a Consultation

Indications and Usage Wegovy (semaglutide) injection is indicated in combination with a reduced calorie diet and increased physical activity: To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight To reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbidity Wegovy (semaglutide) tablets are indicated in combination with a reduced calorie diet and increased physical activity to: Reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight Reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight in the presence of at least one weight-related comorbidity Limitations of Use: Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended Reference Wegovy [package insert]

On the other hand, Saxenda (liraglutide) requires a more hands-on approach, with a daily injection schedule

AST and ALT were measured using enzymatic UV kinetic methods in accordance with International Federation of Clinical Chemistry (IFCC) standards, with NADH consumption monitored at 340 nm